Cell Biotech Co

Cell Biotech Co EBITDA Margin

The EBITDA Margin of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 14.90 %. In the previous year, EBITDA Margin was 18.84 % — a change of -20.93% (lower).

EBITDA Margin

14.90 %

YoY

-20.93%

Last updated:

EBITDA Margin of Cell Biotech Co is 2025 14.90 % . EBITDA Margin of Cell Biotech Co was 2024 18.84 % . It decreases by -20.93% lower compared to the previous year.

The Cell Biotech Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
36.00 KRW
Jan 1, 2019
16.08 KRW
Jan 1, 2020
13.43 KRW
Jan 1, 2021
20.86 KRW
Jan 1, 2022
17.03 KRW
Jan 1, 2023
8.88 KRW
Jan 1, 2024
18.84 KRW
Jan 1, 2025
14.90 KRW
The Cell Biotech Co EBITDA Margin history
YEAREBITDA MarginYoY
14.90 %-20.93%
18.84 %+112.20%
8.88 %-47.85%
17.03 %-18.40%
20.86 %+55.30%
13.43 %-16.47%
16.08 %-55.32%
36.00 %-5.88%
38.25 %+0.68%
37.99 %-2.17%
38.83 %+19.36%
32.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

EBITDA Margin of Cell Biotech Co is 14.90 % in 2025.

EBITDA Margin of Cell Biotech Co changed from 18.84 % to 14.90 %, representing a -20.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cell Biotech Co

All Key Metrics — Cell Biotech Co